Condition: Recurrent Pericarditis · Sponsor: Cardiol Therapeutics Inc.
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.
This description comes directly from the study's public registry record.
Andrea B Parker, MSc., PhD · +1 289 910 0862 · andrea.parker@cardiolrx.com
Heather Dalgleish, MSc. · +1 289 910 0384 · heather.dalgleish@cardiolrx.com
Always discuss trial participation with your own doctor first.
| Mayo Clionic Arizona | Phoenix, Arizona, United States | Recruiting |
| UCI Health | Irvine, California, United States | Recruiting |
| Altman Clinical and Translational Research Institute | La Jolla, California, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Not Yet Recruiting |
| Pacific Heart Institute at Cedars-Sinai | Santa Monica, California, United States | Recruiting |
| Mayo Clinic Florida | Jacksonville, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| MedStar Health Institute | Columbia, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Minneapolis Heart Institute | Minneapolis, Minnesota, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06708299